AMPH Q2 2021 Earnings — Amphastar Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AMPHAmphastar Pharmaceuticals, Inc.

$860M

Q2 2021 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$102M+18.5% YoY

Gross Profit

$47M46.6% margin

Operating Income

$11M10.4% margin

Net Income

$8M7.6% margin

EPS (Diluted)

$0.16

QoQ Revenue Growth

-1.3%

Cash Flow

Operating Cash Flow

$32M

Free Cash Flow

$26M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$666M

Total Liabilities

$199M

Stockholders' Equity

$422M

Cash & Equivalents

$125M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$102M	$86M	+18.5%
Gross Profit	$47M	$33M	+42.8%
Operating Income	$11M	-$3M	+461.4%
Net Income	$8M	-$192,000	+4145.3%

Revenue Segments

Active Pharmaceutical Ingredient Segment

$7M100%

Geographic Segments

U

$95M99%

C

$1M1%